Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478395 | 1.00 | KMT2A (0.55) | KMT2AALDH1A1KDM4ESIGMAR1OPRM1 | |
| SCHEMBL5469268 | 1.00 | KMT2A (0.55) | KMT2AALDH1A1KDM4ESIGMAR1OPRM1 | |
| SCHEMBL5480842 | 0.92 | KMT2A (0.57) | KMT2AALDH1A1KDM4ESIGMAR1OPRM1 | |
| SCHEMBL4872137 | 0.87 | OPRM1 (0.70) | KMT2AALDH1A1SIGMAR1OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL8355555 | 0.86 | OPRM1 (0.68) | KMT2AALDH1A1SIGMAR1OPRM1OPRL1 | |
| SCHEMBL9435333 | 0.86 | OPRM1 (0.71) | OPRM1HTR1DOPRL1 | |
| SCHEMBL9435497 | 0.86 | OPRM1 (0.71) | OPRM1HTR1DOPRL1 | |
| SCHEMBL5475211 | 0.85 | KMT2A (0.54) | KMT2ASIGMAR1OPRM1CHRM2CHRM3 | |
| SCHEMBL5475207 | 0.85 | KMT2A (0.54) | KMT2ASIGMAR1OPRM1CHRM2CHRM3 | |
| SCHEMBL5475853 | 0.85 | KMT2A (0.75) | KMT2AALDH1A1SIGMAR1OPRM1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KMT2A 1301/4885ALDH1A1 2990/4885KDM4E 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.